ProMIS Neurosciences Inc.
For the period ended Nov 12, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 12, 2025 · Filed Nov 12, 2025
PMN$4.16+14.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Key Pipeline Programs
Key Pipeline Programs
| ● | Amyotrophic Lateral Sclerosis Disease Program (PMN267) |
| o | PMN267 is a humanized IgG1 antibody directed against toxic misfolded TDP-43 as a potential therapeutic target for ALS and is ready to progress to IND-enabling studies. |
| ● | Parkinson’s Disease (PD) and Multiple System Atrophy (MSA) Disease Program (PMN442) |
| o | PMN442 is a humanized IgG1 antibody and is ProMIS’s lead candidate for PD, MSA and other synucleinopathies based on its selective binding and protective activity against pathogenic forms of alpha-synuclein and is ready to progress to IND-enabling studies. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.